AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023 (English only)
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it will host a KOL webinar on amyloid plaque PET imaging in Alzheimer’s Disease as a surrogate of clinical efficacy on Thursday, November 9, 2023 at 10:00am ET / 4:00pm CET. To register, click here.
The event will feature Prof. Victor Villemagne, MD (University of Pittsburgh), who will discuss the heightened interest in amyloid plaque PET imaging and the methodology, mechanisms, and clinical implications of plaque lowering in light of recent successful trials.
The AC Immune team will also highlight its anti-Abeta active immunotherapy candidate, ACI-24.060, currently being evaluated in the ongoing Phase 1b/2 ABATE study for the treatment of Alzheimer’s disease. Initial amyloid-PET imaging analyses in Alzheimer’s patients to assess amyloid plaque reduction after 6 months of treatment with ACI-24.060 in the ABATE trial are anticipated in the first half of 2024.
A live question and answer session will follow the presentations.